TP53 and ovarian carcinoma: Cisplatin resistance is one of the most common forms of chemoresistance in ovarian cancer, and studies have shown that SIRT1 overexpression in ovarian cancer cells enhances resistance to cisplatin treatment by reducing the activity of p53.